Evidence map›Paper›PMID 29572286›Full record

Observational studyClinical journal of the American Society of Nephrology : CJASN2018

Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.

Emily B Schroeder, Michel Chonchol, Susan M Shetterly, J David Powers, John L Adams, Julie A Schmittdiel, Gregory A Nichols, Patrick J O'Connor, John F Steiner

Open access · bronzeAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical journal of the American Society of Nephrology : CJASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus.International journal of diabetes in developing countries · 2022
    Review
  3. Tight Blood Pressure Control in Chronic Kidney Disease.Journal of cardiovascular development and disease · 2022
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Emily B SchroederInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.ORCID 0000-0002-6323-4790
Michel ChoncholRenal Diseases and Hypertension, University of Colorado Denver, Aurora, Colorado.
Susan M ShetterlyInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
J David PowersInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
John L AdamsCenter for Effectiveness and Safety Research, Kaiser Permanente, Pasadena, California.
Julie A SchmittdielDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Gregory A NicholsCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and.
Patrick J O'ConnorHealthPartners Institute and HealthPartners Center for Chronic Care Innovation, Minneapolis, Minnesota.
John F SteinerInstitute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado.
Kaiser Permanente · USHealthPartners · USKaiser Permanente Center for Health Research · USUniversity of Colorado Denver · US

Funding

Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Alyce Sophia Adams, HILARY Kessler SELIGMAN · 2011 to 2026
$9.2M
Multi-institutional Consortium for CER in Diabetes Treatment and PreventionR01HS019859 · AHRQ · KAISER FOUNDATION RESEARCH INSTITUTE · PI STEINER, JOHN F · 2010 to 2010
$8.9M
Blood Pressure and Progression of Diabetic Kidney DiseaseK23DK099237 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI SCHROEDER, EMILY BARTLETT · 2014 to 2018
$869k
SUPREME-DM: Sustaining a Learning Research NetworkR01HS022963 · AHRQ · KAISER FOUNDATION RESEARCH INSTITUTE · PI STEINER, JOHN F · 2013 to 2013
$749k
AHRQ HHS R01 HS019859AHRQ HHS R01 HS022963NIDDK NIH HHS K23 DK099237NIDDK NIH HHS P30 DK092924
6 · The paper itself

Abstract

BACKGROUND AND

objectivesIn individuals with diabetes, the comparative effectiveness of add-on antihypertensive medications added to an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker on the risk of significant kidney events is unknown. DESIGN, SETTING PARTICIPANTS, & MEASUREMENTS: We used an observational, multicenter cohort of 21,897 individuals with diabetes to compare individuals who added

resultsOver a maximum of 5 years, there were 4707 significant kidney events, 1498 deaths, and 818 cardiovascular events. Compared with thiazide diuretics, hazard ratios for significant kidney events for

conclusionsCompared with thiazide diuretics, calcium channel blockers were associated with a lower risk of significant kidney events and a similar risk of cardiovascular events.

Indexed as

AgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersDiabetes ComplicationsDrug Therapy, CombinationFemaleGlomerular Filtration RateHumansHypertensionKidneyMaleMiddle AgedProportional Hazards ModelsSodium Chloride Symporter InhibitorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersSodium Chloride Symporter InhibitorsAcute Coronary SyndromeAdrenergic beta-AntagonistsaldosteroneAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsAntihypertensive AgentsCalcium Channel Blockerscardiovascular diseaseCohort StudiesCoronary Artery Bypassdiabetes mellitusDihydropyridinesheart failurehypertensionkidney diseaseMyocardial InfarctionPeptidyl-Dipeptidase APercutaneous Coronary InterventionPropensity ScoreProportional Hazards ModelsSodium Chloride Symporter InhibitorsSodium Potassium Chloride Symporter InhibitorsStroke

Identifiers

PMID29572286
PMCPMC5969476
OpenAlexW2793186959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.